Biologics, Delivered Inside the Cell
Unlocking Intracellular Delivery for Next-Generation Biologics
Permeasis Therapeutics is building a platform to address one of biotechnology’s most enduring challenges: delivering biologically active macromolecules inside cells. By enabling intracellular delivery of proteins and other large therapeutic payloads to the cytosol and other intracellular compartments, Permeasis aims to expand the reach of biologics to diseases that have remained inaccessible to current therapeutics.
News
Permeasis Therapeutics and The Ohio State University Publish Foundational Research on Intracellular Delivery Technology in ACS Chemical Biology
Membrane Translocation Domain (MTD) platform demonstrates a potential solution to one of biotechnology’s most persistent challenges: delivering therapeutic proteins inside cells.
Our Science
Permeasis Therapeutics is developing a platform designed to deliver biologically active macromolecules inside cells, addressing one of the central barriers in biotechnology. By enabling proteins and other large therapeutic payloads to reach the cytosol and intracellular organelles, Permeasis aims to expand the reach of biologics beyond extracellular and lysosomal targets toward diseases that have remained difficult to treat.
-
Permeasis is built around Membrane Translocation Domain, or MTD, technology, designed to overcome key bottlenecks that limit the reach of current biologics.
When genetically fused to therapeutic payloads, MTDs enable efficient cellular uptake and endosomal escape, allowing proteins and other macromolecules to access the intracellular environment where many disease processes originate. By delivering functional copies of faulty, disease-driving proteins and other therapeutic payloads directly inside cells, MTD-enabled medicines have the potential to address diseases that remain beyond the reach of conventional biologics, small molecules, and genetic medicines.
Permeasis is initially applying its platform to genetically defined diseases where intracellular delivery of functional proteins could have meaningful therapeutic impact, while also exploring the broader potential of MTD-enabled delivery for multiple classes of macromolecular medicines.
Permeasis Therapeutics, Inc.
349 Newbury Street, 2nd Floor
Boston, MA 02115
© 2026 Permeasis Therapeutics, Inc. All rights reserved.